TY  - JOUR
T1  - Increasing cases of Orbital Mucormycosis in recent years
AU  - Oğuz, Halit
AU  - Yılmaz, Ömer
PY  - 2021
DA  - April
Y2  - 2021
JF  - Clinical and Experimental Ocular Trauma and Infection
JO  - CEOTI
PB  - Sertaç Argun KIVANÇ
WT  - DergiPark
SN  - 2667-8462
SP  - 10
EP  - 11
VL  - 3
IS  - 1
LA  - en
AB  - Mucormycosis is a uncommon but aggressive and lethal fungal infection, which can rapidly spread especially in immunosuppressed patients. In recent years, there has been a serious increase in the number of orbital mucormycosis cases and publications. Mucormycosis prevalence in India is approximately 70 times more than the prevalence in developed countries. Diabetes mellitus, immunosuppression and trauma are major risk factors. Recently, COVİD-19 disease is common. COVID-19 infection and its treatment lead to immunosuppression, this has made patients vulnerable to secondary infections, including mucormycosis. Ophthalmologists should be aware of the possible vision threatening complications.
KW  - mucormycosis
KW  - covid19
KW  - pandemic
KW  - ocular infection
CR  - Prakash H, Chakrabarti A. Epidemiology of Mucormycosis in India. Microorganisms. 2021;9(3):523.
CR  - Dadhich A, Nilesh K, Patil R, Saluja H. Unusual presentation of mucormycosis mimicking a localised sino-orbital pathology. BMJ Case Rep. 2021;14(1).
CR  - Sarkar S, Gokhale T, Choudhury SS, Deb AK. COVID-19 and orbital mucormycosis. Indian J Ophthalmol. 2021;69(4):1002-4.
CR  - Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. Eur J Ophthalmol. 2021;10(4)
CR  - Mtibaa L, Halwani C, Tbini M, et al. Successful treatment of rhino-facial mucormycosis in a diabetic patient. Med Mycol Case Rep. 2020;27:64-7.
UR  - https://dergipark.org.tr/en/pub/ceoti/article/949410
L1  - https://dergipark.org.tr/en/download/article-file/1812657
ER  -